APADAZ (benzhydrocodone and acetaminophen) by Zevra Therapeutics is hydrocodone. First approved in 2018.
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
APADAZ is a fixed-dose combination oral tablet containing benzhydrocodone (a semi-synthetic opioid agonist) and acetaminophen for moderate to severe acute pain management. Hydrocodone acts as a mu-opioid receptor agonist to provide analgesia without a ceiling effect, while acetaminophen provides complementary non-opioid analgesia through central mechanisms. The combination leverages multimodal pain relief to optimize efficacy while potentially reducing opioid dose requirements.
Product is at peak lifecycle stage with 11 linked positions, indicating stable commercial investment and multi-functional team engagement across medical affairs, HR, and patient services.
hydrocodone. Hydrocodone Hydrocodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of hydrocodone is analgesia. Like all full opioid agonists, there is no ceiling…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on APADAZ at Zevra Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LOE in ~5 years — strategic planning for patent cliff underway
Working on APADAZ offers exposure to peak-stage brand management, medical affairs strategy, and cross-functional project execution with emphasis on competitive defense and regulatory compliance. The product provides mid-career development opportunities in leadership and strategic planning ahead of a predictable LOE transition in 2030-2031.
11 open roles linked to this drug
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo